Cargando…

DMARD disruption, disease flare, and prolonged symptom duration after acute COVID-19 among participants with rheumatic disease: A prospective study

OBJECTIVE: To describe disease-modifying antirheumatic drug (DMARD) disruption, rheumatic disease flare/activity, and prolonged COVID-19 symptom duration among COVID-19 survivors with systemic autoimmune rheumatic diseases (SARDs). METHODS: We surveyed patients with SARDs after confirmed COVID-19 at...

Descripción completa

Detalles Bibliográficos
Autores principales:	Di Iorio, Michael, Cook, Claire E., Vanni, Kathleen M.M., Patel, Naomi J., D’Silva, Kristin M., Fu, Xiaoqing, Wang, Jiaqi, Prisco, Lauren C., Kowalski, Emily, Zaccardelli, Alessandra, Martin, Lily W., Qian, Grace, Hsu, Tiffany Y-T., Wallace, Zachary S., Sparks, Jeffrey A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cold Spring Harbor Laboratory 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8845434/ https://www.ncbi.nlm.nih.gov/pubmed/35169813 http://dx.doi.org/10.1101/2022.02.08.22270696

Ejemplares similares

DMARD disruption, rheumatic disease flare, and prolonged COVID-19 symptom duration after acute COVID-19 among patients with rheumatic disease: A prospective study
por: Di Iorio, Michael, et al.
Publicado: (2022)

COVID-19 Outcomes Among Users of CD20 Inhibitors for Immune-Mediated Diseases: A Comparative Cohort Study
por: Patel, Naomi J., et al.
Publicado: (2021)

Laboratory trends, hyperinflammation, and clinical outcomes for patients with a systemic rheumatic disease admitted to hospital for COVID-19: a retrospective, comparative cohort study
por: Hsu, Tiffany Y-T, et al.
Publicado: (2021)

Coronavirus Disease 2019 Outcomes Among Recipients of Anti‐CD20 Monoclonal Antibodies for Immune‐Mediated Diseases: A Comparative Cohort Study
por: Patel, Naomi J., et al.
Publicado: (2021)

Incident systemic rheumatic disease following COVID-19
por: Hsu, Tiffany Y-T, et al.
Publicado: (2021)

Factors associated with COVID-19 breakthrough infection among vaccinated patients with rheumatic diseases: A cohort study
por: Patel, Naomi J., et al.
Publicado: (2023)

Breakthrough infection after three doses of COVID-19 mRNA vaccine in systemic autoimmune rheumatic diseases: two cases in patients on TNF inhibitor monotherapy
por: Vanni, Kathleen MM, et al.
Publicado: (2022)

Temporal trends in COVID-19 outcomes among patients with systemic autoimmune rheumatic diseases: From the first wave to Omicron
por: Kawano, Yumeko, et al.
Publicado: (2022)

Clinical characteristics and outcomes of patients with coronavirus disease 2019 (COVID-19) and rheumatic disease: a comparative cohort study from a US ‘hot spot’
por: D’Silva, Kristin M, et al.
Publicado: (2020)

COVID-19 and Disease-Modifying Anti-rheumatic Drugs
por: D’Silva, Kristin M., et al.
Publicado: (2021)

Stopping bDMARDs at the beginning of pregnancy is associated with disease flares and preterm delivery in women with rheumatoid arthritis
por: Gerardi, Maria Chiara, et al.
Publicado: (2022)

Tapering glucocorticoids and risk of flare in rheumatoid arthritis on biological disease-modifying antirheumatic drugs (bDMARDs)
por: Adami, Giovanni, et al.
Publicado: (2023)

Characteristics and evolution of 38 patients with rheumatic diseases and COVID-19 under DMARD therapy
por: Galarza-Delgado, Dionicio Ángel, et al.
Publicado: (2020)

Optical tomographic imaging discriminates between disease-modifying anti-rheumatic drug (DMARD) and non-DMARD efficacy in collagen antibody-induced arthritis
por: Peterson, Jeffrey D, et al.
Publicado: (2010)

Does COVID-19 cause an increased risk of hospitalization or death in patients with inflammatory rheumatic diseases treated with biological DMARDs or targeted synthetic DMARDs?
por: Lwin, May, et al.
Publicado: (2020)

Immunogenicity, breakthrough infection, and underlying disease flare after SARS-CoV-2 vaccination among individuals with systemic autoimmune rheumatic diseases
por: Paik, Julie J., et al.
Publicado: (2022)

Outcomes with and without outpatient SARS-CoV-2 treatment for patients with COVID-19 and systemic autoimmune rheumatic diseases: A retrospective cohort study
por: Qian, Grace, et al.
Publicado: (2022)

Flare during tapering of biological DMARDs in patients with rheumatoid arthritis in routine care: characteristics and predictors
por: Terslev, L, et al.
Publicado: (2022)

Changes in the use patterns of bDMARDs in patients with rheumatic diseases over the past 13 years
por: Sánchez-Piedra, Carlos, et al.
Publicado: (2021)

Outcomes with Biological Disease-Modifying Anti-Rheumatic Drugs (bDMARDs) in Older Patients Treated for Rheumatoid Arthritis
por: Akter, Ripa, et al.
Publicado: (2020)

Cost-utility analysis of biologic disease-modifying antirheumatic drugs (bDMARDs), targeted synthetic DMARDs (tsDMARDs) and biosimilar DMARDs (bsDMARDs) combined with methotrexate for Thai rheumatoid arthritis patients with high disease activity
por: Prawjaeng, Juthamas, et al.
Publicado: (2023)

‘Should we stop or continue conventional synthetic (including glucocorticoids) and targeted DMARDs before surgery in patients with inflammatory rheumatic diseases?’
por: Goodman, Susan M, et al.
Publicado: (2020)

Seronegative rheumatic arthritis has milder inflammation and bone erosion in an ultrasound study of disease-modifying anti-rheumatic drugs (DMARDs)-naïve Chinese cohort
por: Lin, Dongfang, et al.
Publicado: (2022)

The Flare of Rheumatic Disease After SARS-CoV-2 Vaccination: A Review
por: Xie, Yan, et al.
Publicado: (2022)

Outcomes with and without outpatient SARS-CoV-2 treatment for patients with COVID-19 and systemic autoimmune rheumatic diseases: a retrospective cohort study
por: Qian, Grace, et al.
Publicado: (2023)

Saudi cultural adaptation of the “compliance questionnaire of Rheumatology” for Rheumatoid arthritis patients on disease modifying anti-rheumatic drugs (DMARDs)
por: Aljohani, Roaa, et al.
Publicado: (2021)

Factors associated with radiographic progression in rheumatoid arthritis starting biological diseases modifying anti-rheumatic drugs (bDMARDs)
por: Adami, Giovanni, et al.
Publicado: (2023)

The pharmacological and clinical aspects behind dose loading of biological disease modifying anti-rheumatic drugs (bDMARDs) in auto-immune rheumatic diseases (AIRDs): rationale and systematic narrative review of clinical evidence
por: Geurts-Voerman, Gerlienke E., et al.
Publicado: (2020)

Predictors of low spike antibody response in patients with systemic rheumatic disease after an initial course of COVID-19 vaccination
por: Whelan, Mary Grace, et al.
Publicado: (2023)

Clinical factors associated with discontinuation of ts/bDMARDs in rheumatic patients from the BIOBADASER III registry
por: Prior-Español, A., et al.
Publicado: (2021)

Evaluating patient reported outcomes in routine practice of patients with rheumatoid arthritis treated with biological disease modifying anti rheumatic drugs (b-DMARDs)
por: Boone, Niels W., et al.
Publicado: (2015)

404. Impact of cross-coronavirus humoral immunity in post-acute sequelae of COVID-19 in systemic autoimmune rheumatic diseases patients
por: Herman, Jonathan, et al.
Publicado: (2023)

Intraarticular steroids as DMARD-sparing agents for juvenile idiopathic arthritis flares: Analysis of the Childhood Arthritis and Rheumatology Research Alliance Registry
por: Hahn, Timothy, et al.
Publicado: (2022)

Temporal trends in severe COVID-19 outcomes in patients with rheumatic disease: a cohort study
por: Jorge, April, et al.
Publicado: (2021)

A Roadmap for Investigating Preclinical Autoimmunity Using Patient-Oriented and Epidemiologic Study Designs: Example of Rheumatoid Arthritis
por: Kowalski, Emily N., et al.
Publicado: (2022)

The Impact of Low-Dose Disease-modifying Anti-rheumatics Drugs (DMARDs) on Bone Mineral Density of Premenopausal Women in Early Rheumatoid Arthritis
por: Rexhepi, Sylejman, et al.
Publicado: (2016)

HBV and targeted synthetic (ts)DMARDs: what have we learned from bDMARDs and tsDMARDs?
por: Gremese, Elisa, et al.
Publicado: (2020)

Rare reports of rheumatic disorder flares after COVID-19 vaccination
Publicado: (2022)

Prolonged COVID-19 symptom duration in people with systemic autoimmune rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey
por: DiIorio, Michael, et al.
Publicado: (2022)

Correction: Intraarticular steroids as DMARD-sparing agents for juvenile idiopathic arthritis flares: Analysis of the Childhood Arthritis and Rheumatology Research Alliance Registry
por: Hahn, Timothy, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_d5h1685ahkq4uap0so7bkqfp5i